Helminthosis
Conditions
Interventions
Albendazole
BALEG Syrup
Sponsors
Health Sciences Research Institute
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: • infected with intestinal parasites ; • are between 5 and 15 years of age; • have given their consent for children aged between 12 and 15 years; • have parents or guardians who have signed the informed consent form; • be able to take the drug orally; • have visited a health facility at the study site; • reside in the geographical area of the sites for the duration of the treatment; • accept the study procedures.
Exclusion criteria
Exclusion criteria: • undergoing specific treatment for intestinal parasitosis ; • with known allergies to the study drugs or any of their components; • participating in any other ongoing clinical study; • with biochemical parameters (transaminases, creatinemia, urea) above normal; • have a chronic pathology: cancer, asthma, renal or hepatic insufficiency; • with serious neurological or mental disorders.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Parasite clearence (negative Kato-Katz stool test) in 95% of patients;Occurrence of a serious adverse event | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Improvement of clinical signs of intestinal parasitic infection such as diarrhea, abdominal pain, vomiting, or fever at any time after Day 3, or worsening of clinical condition compared to baseline 2.A difference of less than 10% in the reduction of parasite eggs in patients receiving BALEG Syrup compared to those receiving Albendazole 3. Acceptability of the BALEG Syrup phytomedicine among children | — |
Countries
Burkina Faso
Contacts
Public ContactBelemlilga Mohamed
Health Science research institute
Outcome results
None listed